Adocia SA · EURONEXT:ADOC

Adocia SA — Shareholder Meeting (May 2021)

65 slides from Adocia SA's shareholder meeting presentation, May 20, 2021

  1. Slide 1: Shareholders' meeting May 20th 2021

    Slide 1: Shareholders' meeting May 20th 2021

    Shareholders’ meeting May 20th 2021 Adocia – 115, avenue Lacassagne – 69003 Lyon

  2. Slide 2: Speakers

    Slide 2: Speakers

    Speakers Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager President and CEO R&D Director Chief Financial Officer Shareholders’ meeting May 20th 2021 2

  3. Slide 3: Quorum

    Slide 3: Quorum

    QUORUM Shareholders’ meeting May 20th 2021 3

  4. Slide 4: Agenda

    Slide 4: Agenda

    Agenda • Highlights and progress 2020 et H1 2021 • Perspectives H2 2021 et 2022 • Presentation of the 2020 financial statements • Presentation of the statutory auditors' reports conclusions • Presentation of resolutions and voting results Shareholders’ meeting May 20th 2021 4

  5. Slide 5: 2020 overview, Covid context and perspectives

    Slide 5: 2020 overview, Covid context and perspectives

    2020 overview, Covid context and perspectives Shareholders’ meeting May 20th 2021 5

  6. Slide 6: 2020 overview, Covid context and perspectives

    Slide 6: 2020 overview, Covid context and perspectives

    2020 overview, Covid context and perspectives Thanks to all our employees who have shown great solidarity and resilience during this difficult period while respecting the sanitary rules imposed • Overview: • Achievement of all set operational objectives • Continued relentless search for partners for

  7. Slide 7: Key events and progress 2020 and H1 2021, Perspectives H2 2021 and 2022

    Slide 7: Key events and progress 2020 and H1 2021, Perspectives H2 2021 and 2022

    Key events and progress 2020 and H1 2021 Perspectives H2 2021 and 2022 Shareholders’ meeting May 20th 2021 7

  8. Slide 8: Key events 2020 and H1 2021

    Slide 8: Key events 2020 and H1 2021

    Key events 2020 and H1 2021 In an unprecedented context linked to the coronavirus pandemic 1. The objectives set for the projects have been achieved – PART 1 - • Milestones achieved in China with our partner THDB o BC Lispro: submission by our Chinese partner of the clinical file to the CDE o BC Com

  9. Slide 9: Key events 2020 and H1 2021

    Slide 9: Key events 2020 and H1 2021

    Key events 2020 and H1 2021 1. The objectives set for the projects have been achieved – PART 2 - • Clinical Advance on Insulin/Pramlintide Combinations o Positive Phase 1b results for M1Pram and launch of a Phase 2 study o Preparation of a Phase 1 clinical study of BC LisPram in pump o Licensing opp

  10. Slide 10: A well-advanced pipeline with products ready to partner

    Slide 10: A well-advanced pipeline with products ready to partner

    A well-advanced pipeline with products ready to partner Preclinic Phase I Phase II Phase III Upcoming milestones BC Lispro Phase 3 in China expected in 2021 Ultra-Rapid Insulin U100 / U200 Phase 3 EU/US expected in 2022 Insulins Combination BC Combo U200 Phase 1 in China : 2021 Glargine + Lispr M1Pr

  11. Slide 11: M1Pram and BC LisPram / BC AsPram

    Slide 11: M1Pram and BC LisPram / BC AsPram

    M1Pram & BC LisPram / BC AsPram Insulin-Amylin 2-in-1 products: a therapeutic breakthrough Shareholders’ meeting May 20th 2021 11

  12. Slide 12: Glycemic control requires the synchronized action of insulin and amylin

    Slide 12: Glycemic control requires the synchronized action of insulin and amylin

    Glycemic control requires the synchronized action of insulin and amylin Meal Without diabetes Pancreas Insulin Level of secretion (relative scale) Amylin Insulin Glucagon Produced 0 1 2 3 4 5 6 Produced Glucagon by α-cells Time (hours) by β-cells Meal With diabetes Level of secretion Glucagon is dys

  13. Slide 13: Symlin (pramlintide) was approved by FDA in 2005

    Slide 13: Symlin (pramlintide) was approved by FDA in 2005

    Symlin® (pramlintide, an amylin analog) was approved by FDA in 2005 as an adjunct to insulin treatment for T1D and T2D Activates amylin receptors in different brain areas ▪ Satiety ▪ Well-being ✓ Significant weight loss ▪ Protects cognitive functions ✓ Improvement of HbA1c Inhibits glucagon secretio

  14. Slide 14: Adocia is developing insulin-amylin combinations for pen and pump

    Slide 14: Adocia is developing insulin-amylin combinations for pen and pump

    Adocia is developing insulin-amylin combinations for pen and pump Optimal product profile for MDI in pen Optimal product profile for pump Regular insulin analog + Pram Rapid insulin analog + Pram M1Pram BC LisPram BC AsPram Q1 2022: Phase 2 T1D results Q2 2021: Launch Phase 1 T1D MDI: Multiple Daily

  15. Slide 15: Promising Phase 1b results of M1Pram in pen vs Novolog

    Slide 15: Promising Phase 1b results of M1Pram in pen vs Novolog

    Promising Phase 1b results of M1Pram in pen vs Novolog Phase 1b – CT038: n=40 T1D 3-week outpatient trial - M1Pram vs. Novolog (Part B n=16; High dose of insulin) Average glycemia Weight Time In Range 164 0,5 16,2 162 0,4 16 0 15,8 160 -7 mg/dL -2 kg 15,6 -0,5 +58 min Heures 158 p=0,01 mg/dL p=0,006

  16. Slide 16: M1Pram offers better glycemic control and weight loss

    Slide 16: M1Pram offers better glycemic control and weight loss

    M1Pram offers better glycemic control and weight loss M1Pram leverages pramlintide’s clinical “This combination has the potential to finally deliver on the promise of pramlintide benefits for a large number of patients.” ✓ Flatter Post Prandial Glycemia ✓ HbA1c decrease (simulated) Prof. Robert Ratn

  17. Slide 17: BC LisPram: the optimal combination for pumps

    Slide 17: BC LisPram: the optimal combination for pumps

    BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, by Dr. A. Haidar, comparing Lispro in one pump vs Lispro and Pramlintide administered simultaneously in two separate pumps, over one month1 n=29 T1D Results • 10% improvement of Time in

  18. Slide 18: Perspectives H2 2021 et 2022

    Slide 18: Perspectives H2 2021 et 2022

    Perspectives H2 2021 et 2022 • A milestone expected in 2021 with the launch of Phase 3 studies for BC Lispro in China • A unique opportunity to license BC Lispro to the rest of the world • Ambitious clinical program on insulin and pramlintide combinations and unique products to be licensed • A uniqu

  19. Slide 19: Presentation of 2020 financial statements

    Slide 19: Presentation of 2020 financial statements

    Presentation of 2020 financial statements - IFRS rules - French gaap Shareholders’ meeting May 20th 2021 19

  20. Slide 20: Income statement 2020 IFRS

    Slide 20: Income statement 2020 IFRS

    Income statement 2020_ IFRS Shareholders’ meeting May 20th 2021 20

  21. Slide 21: Detail of the operating result IFRS

    Slide 21: Detail of the operating result IFRS

    Detail of the operating result_ IFRS (in m€) Shareholders’ meeting May 20th 2021 21

  22. Slide 22: Balance sheet IFRS

    Slide 22: Balance sheet IFRS

    Balance sheet_IFRS Shareholders’ meeting May 20th 2021 22

  23. Slide 23: Shareholders’ meeting May 20th 2021

    Slide 23: Shareholders’ meeting May 20th 2021

    Shareholders’ meeting May 20th 2021 23

  24. Slide 24: Income statement French Gaap

    Slide 24: Income statement French Gaap

    Income statement_ French Gaap FY 2020 FY 2019 In € thousands French gaap (12 months) (12 months) Net revenue 842 2 622 Reversals of depr./amort.and prov., transfers of charges 334 3 858 Other income 48 17 Operating income 1 225 6 498 Purchase of raw materials ans other supplies (incl. change in inve

  25. Slide 25: Balance Sheet French Gaap

    Slide 25: Balance Sheet French Gaap

    Balance Sheet_ French Gaap In € thousands French gaap 12/31/2020 12/31/2019 In € thousands French gaap 12/31/2020 12/31/2019 Intangible assets - Gross amount 169 169 P aid-up capital 702 696 (Cumulated depreciation and amortization) (146) (121) A dditio nal paid-in capital 79 615 79 621 Intangible a

  26. Slide 26: Intervention of the Auditors

    Slide 26: Intervention of the Auditors

    Intervention of the Auditors Odicéo : Agnès Lamoine Ernst & Young : Mohamed Mabrouk Shareholders’ meeting May 20th 2021 26

  27. Slide 27: Auditors

    Slide 27: Auditors

    Auditors Ernst & Young : Mohamed Mabrouk Odicéo : Agnès Lamoine Shareholders’ meeting May 20th 2021 27

  28. Slide 28: Resolutions submitted to the vote of the shareholders

    Slide 28: Resolutions submitted to the vote of the shareholders

    Resolutions submitted to the vote of the shareholders • 15 resolutions for the Ordinary General Meeting • 16 resolutions for the Extraordinary General Meeting Shareholders’ meeting May 20th 28 2021

  29. Slide 29: Annual Shareholders' Meeting Agenda

    Slide 29: Annual Shareholders' Meeting Agenda

    Annual Shareholders’ Meeting Agenda Shareholders’ meeting May 20th 2021 29

  30. Slide 30: First resolution

    Slide 30: First resolution

    FIRST RESOLUTION Approval of the annual financial statements for the fiscal year closed December 31, 2020 This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 30

  31. Slide 31: Second resolution

    Slide 31: Second resolution

    SECOND RESOLUTION Approval of the consolidated financial statements for the fiscal year closed December 31, 2020 This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 31

  32. Slide 32: Third resolution

    Slide 32: Third resolution

    THIRD RESOLUTION Allocation of income for the fiscal year closed December 31, 2020 This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 32

  33. Slide 33: Fourth resolution

    Slide 33: Fourth resolution

    FOURTH RESOLUTION Review of the agreements specified in Articles L. 225-38 and seq. of the French Commercial Code This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 33

  34. Slide 34: Fifth resolution

    Slide 34: Fifth resolution

    FIFHT RESOLUTION Vote on the information relating to the 2020 compensation of corporate officers (excluding executive corporate officers) mentioned in Article L. 22-10-9 of the French Commercial Code This resolution was adopted with a majority of 99,6% Shareholders’ meeting May 20th 2021 34

  35. Slide 35: Sixth resolution

    Slide 35: Sixth resolution

    SIXTH RESOLUTION Approval of the main components of the compensation for the fiscal year closed December 31, 2020 due or awarded to Mr. Gérard Soula, as Chief Executive Officer This resolution was adopted with a majority of 99,4% Shareholders’ meeting May 20th 2021 35

  36. Slide 36: Seventh resolution

    Slide 36: Seventh resolution

    SEVENTH RESOLUTION Approbation of the main components of the compensation for the fiscal year closed December 31, 2020 due or awarded to Mr. Olivier Soula, Deputy General Manager This resolution was adopted with a majority of 99,4% Shareholders’ meeting May 20th 2021 36

  37. Slide 37: Eighth resolution

    Slide 37: Eighth resolution

    EIGHT RESOLUTION Approval of the compensation policy for the corporate officers awarded for the 2021 fiscal year This resolution was adopted with a majority of 99,2% Shareholders’ meeting May 20th 2021 37

  38. Slide 38: Ninth resolution

    Slide 38: Ninth resolution

    NINTH RESOLUTION Approval of the compensation policy that may be awarded to the Chief Executive Officer, for the 2021 fiscal year This resolution was adopted with a majority of 99,4% Shareholders’ meeting May 20th 2021 38

  39. Slide 39: Tenth resolution

    Slide 39: Tenth resolution

    TENTH RESOLUTION Approval of the compensation policy that may be awarded to the Deputy General Manager, for the 2021 fiscal year This resolution was adopted with a majority of 98,9% Shareholders’ meeting May 20th 2021 39

  40. Slide 40: Eleventh resolution

    Slide 40: Eleventh resolution

    ELEVENTH RESOLUTION Nomination of a new Director for the board Dr. Katherine Bowdish This resolution was adopted with a majority of 99,2% Shareholders’ meeting May 20th 2021 40

  41. Slide 41: Professional summary of Katherine Bowdish

    Slide 41: Professional summary of Katherine Bowdish

    Professional summary of Katherine Bowdish President & CEO of PIC Therapeutics, is a highly experienced professional in the life science sector having co-found several companies working on biological therapies. Beginning in 2013 Dr. Katherine Bowdish worked with Sanofi for seven years where she estab

  42. Slide 42: Twelfth resolution

    Slide 42: Twelfth resolution

    TWELFTH RESOLUTION Nomination of a new Director for the board Dr. Claudia Mitchell This resolution was adopted with a majority of 99,2% Shareholders’ meeting May 20th 2021 42

  43. Slide 43: Professional summary of Claudia Mitchell

    Slide 43: Professional summary of Claudia Mitchell

    Professional summary of Claudia Mitchell Senior VP, Head of Portfolio Strategy, at Astellas Pharma, has a thorough grounding in the biotech sector. Prior to joining Astellas in 2019, she co-founded Universal Cell and served as CEO until Astellas acquired the company only four years later for over $1

  44. Slide 44: Thirteenth resolution

    Slide 44: Thirteenth resolution

    THIRTEEN RESOLUTION Nomination of a new Director for the board Stéphane Boissel This resolution was adopted with a majority of 99,2% Shareholders’ meeting May 20th 2021 44

  45. Slide 45: Professional summary of Stéphane Boissel

    Slide 45: Professional summary of Stéphane Boissel

    Professional summary of Stéphane Boissel Chairman and CEO of SparingVision, is a seasoned biotech professional with over twenty-five years of leadership experience across corporate finance strategy and business development in internationally focused companies. Previously, Stéphane Boissel was Execut

  46. Slide 46: Fourteenth resolution

    Slide 46: Fourteenth resolution

    FOURTEENTH RESOLUTION Determination of the global amount of compensation to be allocated to members of the board of directors This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 46

  47. Slide 47: Fifteenth resolution

    Slide 47: Fifteenth resolution

    FIFTEENTH RESOLUTION Authorization to be given to the Board of Directors for the Company to purchase its own shares This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 47

  48. Slide 48: Extraordinary Shareholders' Meeting Agenda

    Slide 48: Extraordinary Shareholders' Meeting Agenda

    Extraordinary Shareholders’ Meeting Agenda Shareholders’ meeting May 20th 2021 48

  49. Slide 49: Sixteenth resolution

    Slide 49: Sixteenth resolution

    SIXTEENTH RESOLUTION Authorization to be granted to the Board of Directors to reduce stated capital by cancelling shares pursuant to the authorization for the Company to purchase its own shares This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 49

  50. Slide 50: Seventeenth resolution

    Slide 50: Seventeenth resolution

    SEVENTEETH RESOLUTION Delegation of authority to be granted to the Board to increase capital by issuing common shares and/or equity securities without a preemptive subscription right for shareholders and offer to the public (except the offer in paragraph I of the article L. 411-2 of the financial an

  51. Slide 51: Eighteenth resolution

    Slide 51: Eighteenth resolution

    EIGHTEENTH RESOLUTION Delegation of authority to be granted to the Board to increase capital by issuing common shares and/or equity securities without a preemptive subscription right for shareholders as part of an offering provided in paragraph I of Article L. 411-2 of the French Monetary and Financ

  52. Slide 52: Nineteenth resolution

    Slide 52: Nineteenth resolution

    NINETEENTH RESOLUTION Authorization to be granted to the Board to determine the issue price for up to 10% of stated capital, if shares or any equity securities are issued without a preemptive subscription right for shareholders, as set in the seventeenth and eighteenth resolutions This resolution wa

  53. Slide 53: Twentieth resolution

    Slide 53: Twentieth resolution

    TWENTIETH RESOLUTION Delegation of authority to be granted to the Board to increase capital immediately or in the future by issuing common shares and/or equity securities giving access to capital, without a preemptive subscription right for shareholders, in favor of a category of persons satisfying

  54. Slide 54: Twenty-first resolution

    Slide 54: Twenty-first resolution

    TWENTY-FIRST RESOLUTION Delegation of authority to be granted to the Board to increase capital by issuing common shares and/or equity securities, without a preemptive subscription right for shareholders, in favor of a certain category of persons ensuring the underwriting of Company’s equity securiti

  55. Slide 55: Twenty-second resolution

    Slide 55: Twenty-second resolution

    TWENTY SECOND RESOLUTION Delegation of authority granted to the Board of Directors to increase capital by issuing common shares with or without a preemptive subscription right for shareholders as decided in the above-mentioned resolutions This resolution was adopted with a majority of 86,1% Sharehol

  56. Slide 56: Twenty-third resolution

    Slide 56: Twenty-third resolution

    TWENTY THIRD RESOLUTION Delegation of authority granted to the Board of Directors to issue common shares and/or equity securities as part of a public offer comprising an exchange component initiated by the company This resolution was adopted with a majority of 99,2% Shareholders’ meeting May 20th 20

  57. Slide 57: Twenty-fourth resolution

    Slide 57: Twenty-fourth resolution

    TWENTY-FOURTH RESOLUTION Delegation of authority granted to the Board of Directors to decide to issue common shares and/or equity securities giving immediate or deferred access by all means, to shares or other equity securities of the Company, for an amount not exceeding 10% of stated capital, to re

  58. Slide 58: Twenty-fifth resolution

    Slide 58: Twenty-fifth resolution

    TWENTY-FIFTH RESOLUTION Aggregate limits on the issues completed pursuant to the delegations mentioned above (except the delegation of the twenty-first resolution) This resolution was adopted with a majority of 99,6% Shareholders’ meeting May 20th 2021 58

  59. Slide 59: Twenty-sixth resolution

    Slide 59: Twenty-sixth resolution

    TWENTY-SIXTH RESOLUTION delegation of authority granted to the Board of Directors to issue and attribute warrants for shares, without a preemptive subscription right for shareholders, to the profit of (i) board members and advisors at the grant date of the warrants (ii) persons bond by a contract or

  60. Slide 60: Twenty-seventh resolution

    Slide 60: Twenty-seventh resolution

    TWENTY-SEVENTH RESOLUTION Delegation of authority granted to the Board of Directors to grant options to subscribe for or purchase Company shares This resolution was adopted with a majority of 99,2% Shareholders’ meeting May 20th 2021 60

  61. Slide 61: Twenty-eighth resolution

    Slide 61: Twenty-eighth resolution

    TWENTY-EIGHT RESOLUTION Aggregate limits on the amount of issues completed pursuant to the delegations mentioned above This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 61

  62. Slide 62: Twenty-ninth resolution

    Slide 62: Twenty-ninth resolution

    TWENTY-NINTH RESOLUTION Delegation of authority granted to the Board of Directors to increase the share capital through the capitalization of share premiums, profits or other amounts This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 62

  63. Slide 63: Thirtieth resolution

    Slide 63: Thirtieth resolution

    THIRTIETH RESOLUTION Amendment of article 19 of the bylaws Shareholders’ meetings” (specify voting modalities) This resolution was adopted with a majority of 100% Shareholders’ meeting May 20th 2021 63

  64. Slide 64: Thirty-first resolution

    Slide 64: Thirty-first resolution

    THIRSTY-FIRST RESOLUTION Delegation to be granted to the Board to increase stated capital by issuing shares without a preemptive subscription right for shareholders in favor of the employees who participate in a corporate savings plan. This resolution was rejected with 86,3% of votes against Shareho

  65. Slide 65: Thank you for your interest

    Slide 65: Thank you for your interest

    Thank you for your interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks